An Exploratory Trial to Evaluate the Clinical Effectiveness of a Topical Application of BMX-010 in Subjects With Acne Vulgaris.
Latest Information Update: 26 Sep 2023
Price :
$35 *
At a glance
- Drugs BMX-010 (Primary)
- Indications Acne vulgaris; Rosacea
- Focus Therapeutic Use
- Sponsors BioMimetix
- 19 Oct 2020 Status changed from suspended to discontinued.
- 26 Aug 2020 Planned End Date changed from 1 Nov 2022 to 31 Aug 2020.
- 26 Aug 2020 Planned primary completion date changed from 1 Sep 2022 to 31 Aug 2020.